Efficacy of perospirone in the management of aggressive behavior associated with dementia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 4, 2006, Pages 679-683

  Sato, Shinji ^a   Mizukami, Katsuyoshi ^b   Moro, Kazuo ^c   Tanaka, Yoshiro ^c   Asada, Takashi ^a  

^a Tsukuba Memorial Hospital   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Ishizaki Hospital   (Japan)

Author keywords

Aggressive behavior; Behavioral and psychological symptoms of dementia; Dementia; Perospirone

Indexed keywords

DONEPEZIL; DOPAMINE RECEPTOR BLOCKING AGENT; PEROSPIRONE; SEROTONIN ANTAGONIST; TIAPRIDE; VALPROIC ACID;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; FALLING; FEMALE; HUMAN; MALE; MENTAL PATIENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; MUSCLE WEAKNESS; OUTPATIENT; POST HOC ANALYSIS; PSYCHIATRIC DIAGNOSIS; SCORING SYSTEM; SEDATION; SIDE EFFECT; SYMPTOMATOLOGY; UNSTEADINESS; VERBAL BEHAVIOR;

AGED; AGED, 80 AND OVER; AGGRESSION; ANTIPSYCHOTIC AGENTS; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; RETROSPECTIVE STUDIES; THIAZOLES; TIME FACTORS;

EID: 33646077408     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.01.028     Document Type: Article

References (32)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fourth edition (1994), American Psychiatric Press, Washington (DC)
2. American Psychiatric Association. Working Group on Alzheimer's Disease and Related Dementias. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 154 Suppl. 5 (1997) S1-S39
3. Asada T., Kinoshita T., and Kakuma T. Analysis of behavioral disturbances among community-dwelling elderly with Alzheimer's disease. Alzheimer Dis Assoc Disord 14 (2000) 160-167
4. Brodaty H., Ames D., Snowdon J., Woodward M., Kirwan J., Clarnette R., et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. J Clin Psychiatry 64 (2003) 134-143
5. Burns A., Jacoby R., and Levy R. Psychiatric phenomena in Alzheimer's disease: IV. Disorders of behaviour. Br J Psychiatry 157 (1990) 86-94
6. Cantillon M., Brunswick R., Molina D., and Bahro M. Buspirone vs. haloperiol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 4 (1996) 263-267
7. Cohen D., Eisdorfer C., Gorelick P., Paveza G., Luchins D.J., Freels S., et al. Psychopathology associated with Alzheimer's disease and related disorders. J Gerontol Med Sci 48 (1993) M255-M260
8. Cooper J.K., Mungas D., and Weiler P.G. Relation of cognitive status and abnormal behaviors in Alzheimer's disease. J Am Geriatr Soc 38 (1990) 867-870
9. De Deyn P.P., Rabheru K., Rasmussen A., Bocksberger J.P., Dautzenberg P.L.J., Eriksson S., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 (1999) 946-955
10. de Paulis T. Perospirone (Sumitomo Phamaceuticals). Curr Opin Investig Drugs 3 (2002) 121-129
11. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-Mental State: a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res 12 (1975) 189-198
12. Food and Drug Administration. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. April 11, 2005. Available at: http://www.fda.gov/cder/drug/advisory/antipsychotic.htm. Accessed July 21, 2005.
13. Hermann N., and Eryavec G. Buspirone in the management of agitation and aggression associated with dementia. Am J Geriatr Psychiatry 1 (1993) 249-253
14. Hughes C.P., Berg L., Danziger W.L., Coben L.A., and Martin R.L. A new clinical scale for the staging of dementia. Br J Psychiatry 140 (1982) 566-572
15. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A-receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76 (2001) 1521-1531
16. Katz I.R., Jeste D.V., Mintzer J.E., Clyde C., Napolitano J., and Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 60 (1990) 107-115
17. Kudo Y., Nakajima T., Sato M., Sakai T., Otsuski S., Yamawaki S., et al. Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCl on schizophrenia: a comparative double-blind study with mosapramine HCl. Rinsho Hyoka 24 (1997) 207-248 [in Japanese]
18. Lai M.K., Tsang S.W., and Francis P.T. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer's disease. Neuropsychopharmacology 27 (2002) 646-654
19. Linnoila M., Virkkunen M., Scheinin M., Nuutila A., Rimon R., and Goodwin F.K. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 33 (1983) 2609-2614
20. Liperoti R., Gambassi G., Lapane K.L., Chiang C., Pedone C., Mor V., et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 165 (2005) 696-701
21. Lyketsos C.G., Steinberg M., Tschanz J.T., Norton M.C., Steffens D.C., and Breeitner J.C. Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry 157 (2000) 708-714
22. Masui T., Homma H., Kondo C., Osawa T., Iwasaki S., and Matsubara S. Perospirone therapy in elderly patients with schizophrenia. Psychiatr Neurol Jpn 105 (2003) 1247-1253 [in Japanese]
23. Mega M.S., Cummings J.L., Fiorello T., and Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46 (1996) 130-135
24. Mintzer J.E. Underlying mechanisms of psyhosis and aggression in patients with Alzheimer's disease. J Clin Psychiatry 62 Suppl. 21 (2001) S23-S25
25. Murasaki M., Koyama T., Machiyama Y., Yagi G., Kamijima K., Toru M., et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a comparative double-blind study with haloperidol. Rinsho Hyoka 24 (1997) 159-205 [in Japanese]
26. Onrust S.V., and McClellan K. Perospirone. CNS Drugs 15 (2001) 329-337
27. Reisberg B., Borenstein J., Salob S.P., Ferris S.H., Franssen E., and Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 48 Suppl. 5 (1987) S9-S15
28. Sakauye K.M., Camp C.J., and Ford P.A. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1 (1993) 82-84
29. Sato S., Mizukami K., Moro K., Tanaka Y., and Asada T. Beneficial effects of perospirone on aggressive behavior associated with dementia. Psychiatry Clin Neurosci 60 (2006) 106-109
30. Schneider L.S., Pollock V.E., and Lyness S.A. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 38 (1996) 553-563
31. Stanislav S.W., Fabre T., Crismon M.L., and Child A. Buspiron's efficacy in organic-induced aggression. J Clin Psychopharmacol 14 (1994) 126-130
32. Street J.S., Clark W.S., Gannon K.S., Cummings J.L., Bymaster F.P., Tamura R.N., et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57 (2000) 968-976